RELMADA THERAPEUTICS, INC. Proceeds from Notes Payable
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Notes Payable of $6.53 million for the 12-month period ending 2018-06-30, per its 10-KT filed 2020-03-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2020-03-26
- RELMADA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2018-06-30 was $0.00.
- RELMADA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2018-03-31 was $26.70K.
- RELMADA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2017-12-31 was $2.47M.
- RELMADA THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2017-09-30 was $4.04M.
- RELMADA THERAPEUTICS, INC. proceeds from notes payable for fiscal 2018 was $6.53M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 115 month | Proceeds from Notes Payable 118 month |
|---|---|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2020-03-26 | $26.70K derived: sum of 2 quarters · filed 2020-03-26 | $2.50M derived: sum of 3 quarters · filed 2020-03-26 | $6.53M 10-KT · filed 2020-03-26 | ||
| 2018-03-31 | $26.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-15 | $2.50M derived: sum of 2 quarters · filed 2019-05-15 | $6.53M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-13 | $6.51M 10-Q · filed 2019-02-13 | ||||
| 2017-09-30 | $4.04M 10-Q · filed 2018-11-13 | |||||
| 2014-03-31 | $975.00K 8-K · filed 2014-05-27 | |||||
| 2013-12-31 | $975.00K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |